Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

Abstract

Purpose: Despite the accumulation of extensive genomic alterations, many cancers fail to be recognized as "foreign" and escape destruction by the host immune system. Immunotherapies designed to address this problem by directly stimulating immune effector cells have led to some remarkable clinical outcomes, but unfortunately, most cancers fail to respond, prompting the need to identify additional immunomodulatory treatment options.Experimental Design: We elucidated the effect of a novel treatment paradigm using sustained, low-dose HSP90 inhibition in vitro and in syngeneic mouse models using genetic and pharmacologic tools. Profiling of treatment-associated tumor cell antigens was performed using immunoprecipitation followed by peptide mass spectrometry.Results: We show that sustained, low-level inhibition of HSP90 both amplifies and diversifies the antigenic repertoire presented by tumor cells on MHC-I molecules through an IFNgindependent mechanism. In stark contrast, we find that acute, high-dose exposure to HSP90 inhibitors, the only approach studied in the clinic to date, is broadly immunosuppressive in cell culture and in patients with cancer. In mice, chronic nonheat shock-inducing HSP90 inhibition slowed progression of colon cancer implants, but only in syngeneic animals with intact immune function. Addition of a single dose of nonspecific immune adjuvant to the regimen dramatically increased efficacy, curing a subset of mice receiving combination therapy.Conclusions: These highly translatable observations support reconsideration of the most effective strategy for targeting HSP90 to treat cancers and suggest a practical approach to repurposing current orally bioavailable HSP90 inhibitors as a new immunotherapeutic strategy.See related commentary

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition

“…pMHCs were isolated from 1 × 10 7 cells per condition with IP and sizeexclusion filtration, as previously described 58 Briefly, for each condition 0.5 mg of pan-specific anti-human MHC class I (HLA-A, HLA-B, HLA-C) antibody [clone W6/32, Bio X Cell (cat. # BE0079)] was bound to 20 μL FastFlow Protein A Sepharose bead slurry (GE Healthcare) for 3 h rotating at 4°C.…”

Analytic Philosophy for Biomedical Research: The Imperative of Applying Yesterday’s Timeless Messages to Today’s Impasses

“…In the case of cancer immunotherapy, Alex Jaeger and colleagues make the following observation: "Despite the accumulation of extensive genomic alterations, many cancers fail to be recognized as 'foreign' and escape destruction by the host immune system. Immunotherapies designed to address this problem by directly stimulating immune effector cells have led to some remarkable clinical outcomes, but unfortunately, most cancers fail to respond, prompting the need to identify additional immunomodulatory treatment options" [17]. This is compounded by the fact that "the majority of proposed anticancer treatments do not succeed in advancing to clinical use because of problems with efficacy or toxicity, often for unclear reasons" [18].…”

“…In fact, if someone came along and said that a bird embryo is somehow 'trained' to grow wings, people would just laugh, even though embryologists A third, and perhaps the most famous of Aristotle's methodological proposals, is the categorization of causes. In Physics II.3, he introduces the four as follows: 17 Material cause is "that out of which a thing comes to be and which persists", e.g., "the bronze of the statue". Formal cause is "the form or the archetype".…”

Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90

“…If the HSP90i-mediated immunological effects can add to the immunogenic reconditioning of the tumor microenvironment and the stimulation of anti-tumor immunity in vivo which have been observed in the context of radiotherapy ( 91 ) – ideally in a synergistic manner – requires more in-depth analyses. Apparently, the therapeutic success of such approaches in the clinical situation will depend on sequence and dose of both HSP90i and radiation ( 4 , 19 , 92 ).…”